GleamWall
中文EN

NXTS Nexentis Technologies Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1789192 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY18.6%
TTM net income YoY-19.7%
TTM EPS YoY-31,123.8%
Revenue 3-yr CAGR-16.6%
Net income 3-yr CAGR—

Margins

Gross margin65.2%
Operating margin-2,119.7%
Net margin-3,187.1%
FCF margin—
EBITDA margin-2,114.4%

Returns

ROE-92.5%
ROA-78.9%
ROIC (approx.)-126.3%
Asset turnover0.02x

Leverage & solvency

Liabilities / assets21.3%
Debt / equity0.00x
Current ratio4.21x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.42x
Accruals ratio-45.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue—$210,000
Cost of revenue—$165,000
Gross profit—$45,000
R&D expense$179,000$369,000
SG&A expense$5.11M$3.28M
Operating income-$4.23M-$3.28M
Interest expense—$16
Pretax income-$3.61M-$4.32M
Income tax-$18,000—
Net income-$4.00M-$5.19M
EBITDA-$4.16M-$3.27M
EPS (basic)-3.54-27.74
EPS (diluted)-8.61-27.74
Weighted avg. shares (diluted)1.29M187,215
Banking
Net interest income$0-$55,000
Balance sheet
Cash & equivalents$3.83M$2.21M
Short-term investments$239,000$307,000
Receivables$134,000$137,000
Inventory—$21,000
Current assets$6.01M$3.45M
PP&E, net$26,000$48,000
Goodwill$6.29M—
Intangibles$4.43M—
Total assets$20.41M$5.46M
Current liabilities$1.43M$892,000
Short-term debt$740,000—
Total liabilities$4.67M$892,000
Shareholders' equity$16.01M$4.75M
Shares outstanding79,504344,741
Cash flow statement
Operating cash flow-$3.81M-$3.42M
Capital expenditure$14,000—
Free cash flow-$3.82M—
Investing cash flow-$3.23M-$1.89M
Financing cash flow$8.86M$3.05M
Depreciation & amortization$71,000$18,000
Stock-based compensation$91,000$1,000

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.